Search
Gam-COVID-Vac
go.drugbank.com/drugs/DB15848InvestigationalThe vaccine is offered in both a frozen (Gam-COVID-Vac) and freeze-dried formulation (lyophilizate; Gam-COVID-Vac Lyo). … Preliminary results suggested that all participants developed antibodies to the SARS-CoV-2 glycoproteins with a good safety profile in both trials.
Tengonermin
go.drugbank.com/drugs/DB16689Investigational[A233270] A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity.[A233270] … Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug.
LGD-6972
go.drugbank.com/drugs/DB14779InvestigationalLGD-6972 is under investigation in clinical trial NCT01919684 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes
NP-G2-044
go.drugbank.com/drugs/DB14995InvestigationalNP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Lintuzumab satetraxetan AC-225
go.drugbank.com/drugs/DB15053InvestigationalLintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced
International brands: Actimab-AMEDI-6469
go.drugbank.com/drugs/DB15306InvestigationalMEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
MK-0773
go.drugbank.com/drugs/DB16244InvestigationalMK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Modakafusp alfa
go.drugbank.com/drugs/DB16399InvestigationalModakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory
Feladilimab
go.drugbank.com/drugs/DB16415InvestigationalFeladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell
BN‐Brachyury vaccine
go.drugbank.com/drugs/DB17425ExperimentalBN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]
Synonyms: BN‐Brachyury vaccine